CTMP-REV7 Signaling Emerges as a Driver of Immune Escape in MSS Colorectal Cancer
Microsatellite instability-low and microsatellite stable colorectal cancer remains one of the hardest settings for immunotherapy to shift. Low tumor mutational burden leaves fewer neoantigens in play, which narrows the opportunity for checkpoint blockade to generate a durable immune response. In this study, CTMP emerged as a molecule tied to that resistance phenotype, with high expression aligning with poor prognosis and weak antigen presentation in MSI-L/MSS disease.
The central biologic problem is straightforward even if the molecular wiring is not: tumors that reduce MHC-I display can hide from cytotoxic T cells. Here, CTMP was linked to reduced HLA-B expression, stronger immune evasion, and an immunologically “cold” tumor state. The work also connected CTMP to metabolic rewiring, cell-cycle control, and signaling through AKT, suggesting that the protein acts as more than a passive marker of aggressive disease.
Survival, HLA-B Loss, and Resistance to Anti-PD-1 Plus Fruquintinib
Clinical data anchored the mechanistic work. High CTMP expression and low HLA-B expression were each associated with shortened overall survival in patients with MSI-L/MSS colon adenocarcinoma. A separate resistance cohort, consisting of pretreatment specimens from 11 refractory patients receiving anti-PD-1 plus fruquintinib, showed the same direction of effect: progressive disease clustered with the CTMP-high, HLA-B-low pattern.
The implication is direct. When a tumor suppresses class I antigen presentation, it cuts the bridge needed for activated CD8⁺ T cells to recognize and kill malignant cells. In that setting, immune checkpoint blockade has little to amplify, because the tumor has already reduced the visibility of its antigens. The clinical signal here is consistent with that biology and with the disappointing activity often seen in MSS colorectal cancer.
A New CTMP-REV7 Interaction Links Cell Cycle Control to Antigen Presentation
Proteomic screening moved the story into new territory by identifying a previously unreported high-affinity interaction between CTMP and REV7. Structural validation with co-immunoprecipitation, AlphaFold Multimer modeling, GST pulldown experiments, and truncation or point-mutation analysis supported the interaction rather than treating it as an incidental binding event.
REV7 was not simply a passenger in the pathway. The interaction facilitated CDK1-mediated G2/M progression and further repressed HLA-B expression. That coupling matters because proliferative signaling and immune escape often travel together in aggressive tumors. A malignant cell that races through mitosis while simultaneously weakening antigen display gains two advantages at once: faster expansion and lower immune recognition.
One sentence captures the biologic pivot: CTMP-REV7 linked mitotic progression to reduced MHC-I presentation.
CDK1 and AKT Form the Crosstalk Nodes Behind the Immune Phenotype
Mechanistically, the study placed CDK1 and AKT at the center of the pathway. CTMP knockdown or REV7 overexpression reduced CDK1 activity, induced G2/M arrest, and restored HLA-B expression in a manner tied to cGAS signaling relevance. Under IFN-γ-driven immune stress, disruption of the CTMP-REV7 axis altered both CDK1 and AKT activity and changed MHC-I expression.
AKT signaling already has a well-established role in tumor survival, metabolism, and resistance to cell death. In this setting, it appears to serve as a crosstalk node linking immune signaling to transcriptional and post-translational control of antigen presentation. The data also showed that CTMP sustained AKT/PD-L1 signaling and promoted fatty acid metabolism, creating an environment favorable to immune escape and tumor persistence. A cell that can maintain this combination is less likely to be eliminated by endogenous immunity or by immune checkpoint therapy.
The metabolic piece deserves attention. Fatty acid metabolism is not a side hobby of the tumor cell; it supports membrane synthesis, redox balance, and survival under stress. When that pathway is paired with blunted HLA-B expression and PD-L1 signaling, the result is a tumor better equipped to endure inflammatory pressure while remaining less visible to T cells.
Tumor Growth Fell When CTMP Was Silenced or REV7 Was Manipulated
The in vivo data in immunocompetent BALB/c mice with CT26 syngeneic tumors provided functional confirmation. CTMP knockdown or REV7 overexpression suppressed tumor growth, increased HLA-B expression, and improved intratumoral CD8⁺ T-cell infiltration. In other words, restoring the pathway away from CTMP dominance shifted the tumor microenvironment toward immune recognition.
The strongest immune effect came when REV7 overexpression was paired with IFN-γ in CTMP-KD tumors. That combination promoted release of CXCL9, CXCL10, and TNF-α and produced marked tumor regression. These mediators are not decorative biomarkers; CXCL9 and CXCL10 recruit effector T cells, while TNF-α helps sustain inflammatory pressure within the tumor bed. The chemokine surge fits the histologic and functional picture of a tumor becoming more permissive to immune attack.
Another blunt conclusion follows from the animal work: the pathway is modifiable, and the phenotype is reversible enough to matter biologically.
Why This Axis Matters for MSS Colorectal Cancer
MSS colorectal cancer has long represented a low-response subgroup for checkpoint blockade because the tumor is often poorly immunogenic at baseline. This study reframes part of that resistance through a specific signaling axis rather than a vague notion of “cold” biology. CTMP appears to suppress antigen presentation, reinforce AKT-dependent survival signals, promote lipid metabolism, and accelerate cell-cycle progression through REV7 and CDK1.
That architecture offers a plausible explanation for why some tumors remain resistant even when PD-1 is blocked and anti-angiogenic therapy is added. If the tumor cannot present antigen effectively, the immune system is deprived of the very target structure that checkpoint therapy depends on. Restoring HLA-B and MHC-I expression could therefore do more than mark a change in tumor biology; it could recreate the immune visibility needed for treatment to work.
The study is mechanistically rich, but the clinical sample size for the refractory anti-PD-1/fruquintinib cohort was small, and the findings still need prospective validation in larger patient sets. The work nevertheless defines a concrete pathway to test: CTMP-REV7-CDK1, with AKT as the signaling bridge between metabolism, proliferation, and antigen presentation in MSI-L/MSS colorectal cancer.